In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 68 days of free consultation

 

Prognosis of patients with chronic coronary artery disease undergoing to percutaneous coronary intervention (5 years follow-up)

Session Poster Session 3

Speaker Associate Professor Daniil Maximkin

Congress : Heart Failure 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Treatment, Revascularization
  • Session type : Poster Session
  • FP Number : P1786

Authors : Z Shugushev (Moscow,RU), D A Maximkin (Moscow,RU), A Chepurnoy (Moscow,RU), O Safonova (Moscow,RU), A Mambetov (Moscow,RU), A Faibushevich (Moscow,RU), N Sturov (Moscow,RU), V Baranovich (Moscow,RU), G Veretnik (Moscow,RU)

15 views

Authors:
Z Shugushev1 , D A Maximkin1 , A Chepurnoy1 , O Safonova1 , A Mambetov1 , A Faibushevich1 , N Sturov1 , V Baranovich1 , G Veretnik1 , 1RUDN University - Moscow - Russian Federation ,

Citation:

Aim: to evaluate the prognosis of patients with chronic ischemic heart disease, who underwent percutaneous coronary interventions (PCI) and were only on optimal medical therapy (OMT).
Methods: measurement of the fractional flow reserve (FFR) was performed for 432 patients. According to the measurement results, all patients were randomized in 2 groups (1:2): Group I (n=168) – included patients, who had a FFR <0.8 and were followed by PCI; Group II (n=264) – included patients with FFR >0.8 - received OMT and were under monitoring for to 5 years. Inclusion criteria: stable angina II-III FK, post-MI, silent myocardial ischemia. Concomitant diseases: diabetes mellitus (19.2%), multifocal atherosclerosis (21%), hypertension (27%), post-MI (24%), PCI in previously (15%). According to angiography, 44% had a one-vessel disease, 35% had two-vessel diseases, and 21% had a three-vessel disease. Primary endpoints: MACE (death, MI, repeated interventions). Observation periods: 6, 12, 24, 36, 48, 60 months. Long-term results were evaluated by repeated coronary angiography and measurement of FFR.
Results: during 6 and 12 months there were not a single case of MACE in both groups. By the 18th month, 7% of cases conversion from the OMT to the PCI group on the basis of FFR measurements was recorded. By the 24th and 36th months in the OMT, PCI group was performed in 12 and 21% of patients, respectively. By the 48th and 60th month, the number of such patients was 24 and 31%, respectively. Among the total number of performed PCI in Group II, 20% of them were due to unstable angina. Thus, over the entire observation period, 149 patients from group II (56%) had PCI performed. The frequency of MACE in group I to 36 months was 2.4%, and in group II - 18%, respectively (p <0.001). By the end of the observation period, the frequency of MACE in groups I and II was 4.2 and 31%, respectively (p <0.001). Multifactor analysis showed that with SYNTAX score> 28, multifocal atherosclerosis, diabetes mellitus, MACE was significantly more frequent and there was a need to perform PCI in the long-term period.

Conclusions: the prognosis of patients with chronic coronary artery disease undergoing percutaneous coronary intervention, performed using measurement of FFR, is significantly better than in patients who were only on optimal medical therapy.

This content is currently on FREE ACCESS, enjoy another 68 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are